{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:03:54Z","timestamp":1789617834694,"version":"build-2803163510"},"reference-count":32,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2009,3,11]],"date-time":"2009-03-11T00:00:00Z","timestamp":1236729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2009,5]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold>FEIBA<jats:sup>\u00ae<\/jats:sup>(factor eight inhibitor by\u2010passing activity) is used to achieve haemostasis in haemophiliacs with inhibitor. The aim of this study was to evaluate efficacy and consumption of the product in treatment of haemorrhages in haemophiliacs with factor VIII inhibitor, and determine factors that can influence the results of treatment. We used data from our haemophilia centre from years 2000\u20132008. Six haemophiliacs with factor VIII inhibitor were treated on demand with FEIBA<jats:sup>\u00ae<\/jats:sup>for 61 bleeding episodes (45 haemarthroses, six muscle bleeds, six other sites bleeds and four multiple sites bleeds). The median cumulative dose of FEIBA<jats:sup>\u00ae<\/jats:sup>per bleeding episode was 205\u2003U\u2003kg<jats:sup>\u22121<\/jats:sup>. Bleeding was stopped in 96.7% (59 of 61) of events but re\u2010bleeding occurred in 3 events (4.9%) within 48\u2003h after cessation of bleeding. In home treatment (20 of 61) bleeding stopped in 90% (18 of 20) without recurrence and the median consumption per event was reduced to 153\u2003U\u2003kg<jats:sup>\u22121<\/jats:sup>. Without the use of home treatment the median consumption was 250\u2003U\u2003kg<jats:sup>\u22121<\/jats:sup>per event and bleeding ceased definitely in 92.7% (38 of 41) of cases. The cumulative dose of FEIBA<jats:sup>\u00ae<\/jats:sup>was lower for three episodes with re\u2010bleeding: median 96\u2003U\u2003kg<jats:sup>\u22121<\/jats:sup>but not in the two cases of ineffective treatment: 361\u2003U\u2003kg<jats:sup>\u22121<\/jats:sup>. FEIBA<jats:sup>\u00ae<\/jats:sup>in management of bleeding episodes completely resolved the haemorrhage in 91.8% of events and in a further 4.9% if treatment was restarted. Using home treatment saved expenditure due to the lower cumulative dose needed for treatment of haemorrhage.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2009.02012.x","type":"journal-article","created":{"date-parts":[[2009,3,12]],"date-time":"2009-03-12T01:32:30Z","timestamp":1236821550000},"page":"743-751","source":"Crossref","is-referenced-by-count":16,"title":["FEIBA<sup>\u00ae<\/sup>in treatment of acute bleeding episodes in patients with haemophilia A and factor VIII inhibitors: a retrospective survey in regional haemophilia centre"],"prefix":"10.1111","volume":"15","author":[{"given":"P.","family":"SMEJKAL","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"BRABEC","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"MATYSKOVA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"BULIKOVA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"SLECHTOVA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"KISSOVA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"CHLUPOVA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"MUZIK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"PENKA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,4,21]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01296.x"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00780.x"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01284.x"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197407252910402"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01367.x"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V61.1.36.36"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01379.x"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1656122"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1990.30790385521.x"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01366.x"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01735.x"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01449.x"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01403.x"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH05-07-0510"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01772.x"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-017988"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01451.x"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2008.03.002"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07267.x"},{"key":"e_1_2_7_21_2","unstructured":"HemIs registry website: Available athttps:\/\/trials.cba.muni.cz\/trialdb\/interface_forms\/trialdb.asp?name=starttrialdb_hemis(last accessed on 3 July 2008)."},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198109243051301"},{"key":"e_1_2_7_23_2","first-page":"238","article-title":"FEIBA VH in home treatment \u2013 a 3\u2010year prospective experience","volume":"4","author":"Negrier C","year":"1998","journal-title":"Haemophilia"},{"key":"e_1_2_7_24_2","first-page":"31","article-title":"Treatment of patients with high titer inhibitors to factor VIII: a large experience with the use of an activated prothrombin complex concentrate","volume":"2","author":"De Biasi R","year":"1996","journal-title":"Haemophilia"},{"key":"e_1_2_7_25_2","first-page":"540","article-title":"Home treatment with FEIBA\u00ae, the Norwegian experience","volume":"8","author":"Glomstein A","year":"2002","journal-title":"Haemophilia"},{"issue":"2","key":"e_1_2_7_26_2","first-page":"54","article-title":"A Turkish multicenter retrospective study on the efficacy and safety of FEIBA in patients with hemophilia and inhibitors or other rare bleeding disorders","volume":"14","author":"Zulfikar B","year":"2008","journal-title":"Haemophilia"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01601.x"},{"issue":"1","key":"e_1_2_7_28_2","first-page":"156","article-title":"The use of FEIBA and NOVOSEVEN for treatment of bleeding episodes in patients with hemophilia A and factor VIII inhibitor: a single centre experience","volume":"91","author":"Smejkal P","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615388"},{"issue":"63","key":"e_1_2_7_30_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1600-0609.1998.tb01103.x","article-title":"Early treatment with recombinant factor VIIa results in greater efficacy with less product","volume":"61","author":"Lusher JM","year":"1998","journal-title":"Eur J Haematol"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01128.x"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00935.x"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01380.x"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2009.02012.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2009.02012.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T14:52:44Z","timestamp":1710168764000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2009.02012.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,21]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["10.1111\/j.1365-2516.2009.02012.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2009.02012.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,21]]}}}